American National Bank of Texas Takes Position in The Clorox Company $CLX

American National Bank of Texas acquired a new position in shares of The Clorox Company (NYSE:CLX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 7,680 shares of the company’s stock, valued at approximately $947,000. Clorox makes up about 0.9% of American National Bank of Texas’ investment portfolio, making the stock its 23rd largest position.

A number of other hedge funds have also added to or reduced their stakes in CLX. Invesco Ltd. boosted its position in shares of Clorox by 138.3% in the second quarter. Invesco Ltd. now owns 3,245,175 shares of the company’s stock valued at $389,648,000 after acquiring an additional 1,883,465 shares during the period. Norges Bank bought a new position in Clorox in the 2nd quarter valued at $190,429,000. Arrowstreet Capital Limited Partnership boosted its stake in Clorox by 218.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company’s stock valued at $149,983,000 after buying an additional 856,873 shares during the period. Worldquant Millennium Advisors LLC purchased a new position in Clorox during the second quarter worth about $71,856,000. Finally, Hsbc Holdings PLC grew its position in Clorox by 118.8% during the first quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company’s stock worth $159,699,000 after buying an additional 589,544 shares in the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Price Performance

Shares of Clorox stock opened at $103.98 on Monday. The business has a 50 day moving average of $109.89 and a 200 day moving average of $119.14. The company has a quick ratio of 0.50, a current ratio of 0.76 and a debt-to-equity ratio of 18.01. The company has a market cap of $12.68 billion, a PE ratio of 16.32, a P/E/G ratio of 0.52 and a beta of 0.57. The Clorox Company has a 52 week low of $98.20 and a 52 week high of $166.35.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.78 by $0.07. Clorox had a net margin of 11.68% and a return on equity of 358.39%. The company had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $1.41 billion. During the same period in the prior year, the firm posted $1.86 EPS. Clorox’s revenue for the quarter was down 18.9% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. As a group, equities research analysts forecast that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Wednesday, January 28th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 4.8%. The ex-dividend date of this dividend is Wednesday, January 28th. Clorox’s payout ratio is 77.86%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CLX. BNP Paribas Exane dropped their price target on Clorox from $110.00 to $103.00 and set an “underperform” rating for the company in a research report on Tuesday, November 4th. JPMorgan Chase & Co. lowered their target price on shares of Clorox from $127.00 to $120.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 4th. Weiss Ratings reissued a “hold (c-)” rating on shares of Clorox in a research note on Tuesday, October 14th. Barclays decreased their price target on shares of Clorox from $112.00 to $108.00 and set an “underweight” rating on the stock in a report on Tuesday, November 4th. Finally, The Goldman Sachs Group reduced their target price on Clorox from $115.00 to $110.00 and set a “sell” rating on the stock in a research note on Wednesday, October 1st. One equities research analyst has rated the stock with a Buy rating, thirteen have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, Clorox presently has an average rating of “Reduce” and an average target price of $125.69.

Insider Buying and Selling at Clorox

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the firm’s stock in a transaction dated Friday, November 21st. The shares were purchased at an average cost of $104.13 per share, for a total transaction of $416,520.00. Following the transaction, the director owned 13,000 shares of the company’s stock, valued at $1,353,690. This represents a 44.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.63% of the company’s stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.